Lunch Debate

LUNCH DEBATE
12:00 – 13:00, Hall 2

IS THE NEW WHO CLASSIFICATION OF MYELOPROLIFERATIVE DISORDERS A BLESSING?

Chair: H Gisslinger (Medical University of Vienna, Vienna, Austria)

• YES
  A Tefferi (Mayo Clinic, Rochester, USA)
• NO
  J Prchal (University of Utah School of Medicine, Salt Lake City, USA)

LUNCH DEBATE
11:30 – 12:30, Hall 2

SHOULD WE TEST FOR ANTIPLATELET DRUG RESISTANCE?

Chair: C Gachet (Université de Strasbourg, Strasbourg, France)

• YES:

  J Collet (Paris, France)

• NO:

  B Rocca (Catholic University School of Medicine, Chieti, Italy)

LUNCH DEBATE
12:00 – 13:00, Hall 3

FOLLICULAR LYMPHOMA: IS WATCH AND WAIT STILL AN OPTION ?

Chair: R Marcus (King’s College Hospital, London, United Kingdom)

• YES
  M van Oers (Academic Medical Center, Amsterdam, The Netherlands)
• NO
  C Buske (Klinikum Großhadern, Munich, Germany)
  
  

LUNCH DEBATE
12:00 – 13:00, Hall 15.2

SHOULD PATIENTS WITH MYELODYSPLASTIC SYNDROME RECEIVE IRON CHELATION THERAPY?

Chair: E Hellström-Lindberg (Karolinska University Hospital Huddinge, Stockholm, Sweden)

• YES
  L Malcovati (University of Pavia & Fondazione IRCCS Policlinio San Matteo, Pavia, Italy)
• NO
  D Bowen (Leeds Teaching Hospitals, Leeds, United Kingdom)